Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating margin is N/A as of Tuesday, October 6, 2026.
OPERATING MARGIN
N/A
Market Cap
$1.52B
Operating Margin
0.09%
TTM Avg
-3.29%
3Y Avg
-12.30%
5Y Avg
-11595.24%
Market Cap
$1.46B
Operating Margin
20.42%
TTM Avg
-52.76%
3Y Avg
-545.80%
5Y Avg
-384.16%
Market Cap
$1.45B
Operating Margin
7.03%
TTM Avg
2.87%
3Y Avg
2.90%
5Y Avg
2.58%
Market Cap
$1.43B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.39B
Operating Margin
-10386.54%
TTM Avg
-88055.27%
3Y Avg
-48544.96%
5Y Avg
-32630.42%
Market Cap
$1.65B
Operating Margin
-5.55%
TTM Avg
-16.51%
3Y Avg
-27.71%
5Y Avg
-34.02%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.51B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.52B | 0.00% | 0.00% | 0.00% | 0.00% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 0.09% | -3.29% | -12.30% | -11595.24% |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 20.42% | -52.76% | -545.80% | -384.16% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 7.03% | 2.87% | 2.90% | 2.58% |
| Certara, Inc. (CERT)vs › | $1.57B | 1.86% | 2.28% | 0.69% | -0.42% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | 0.00% | 0.00% | 0.00% | 0.00% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | -10386.54% | -88055.27% | -48544.96% | -32630.42% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | -5.55% | -16.51% | -27.71% | -34.02% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 15.35% | 4.65% | 1.95% | -3.05% |
Gross Margin
N/A
Operating Margin
N/A
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
